C 033: IMMUNOTHERAPY FOR NON HODGKIN’S LYMPHOMAS. ADVANCES IN THE USE OF MONOCLONAL ANTIBODIES

J Pharm Pharmacogn Res 2(Suppl. 1): S99, 2014

Special supplement with the abstract book of LATINFARMA 2013

Conference

C 033: IMMUNOTHERAPY FOR NON HODGKIN’S LYMPHOMAS. ADVANCES IN THE USE OF MONOCLONAL ANTIBODIES

Gracia Medina E.

Medical Oncology Department. National Institute of Oncology and Radiobiology, La Habana, Cuba.
Abstract

Immunotherapy has been used systematically for the treatment of non Hodgkin’s Lymphomas (NHL). Modifier of immune response, monoclonal antibodies (MAb) and therapeutics cancer vaccines have shown different grade of outcomes in the management of this heterogeneous disease.

Over the last ten years, the introduction of monoclonal antibodies (MAbs) and specifically the anti-CD20 monoclonal antibody Rituximab has radically changed treatment of B-cell NHL. The use of Rituximab in the treatment of such lymphomas has increased significantly the response rates, the progression free survival and overall survival in both indolent and aggressive B-cell NHL. Based in the results achieved with this drug new strategies of treatment have been developed using MAbs against different epitopes of the CD20 molecule and against other molecules expressed in the surface of lymphoma cell such as CD19, CD22, CD37 and CD30. Moreover, the new drugs such as conjugated antibodies, which are design to carry cytotoxic inside to the target cell; bivalents MAb, and MAb against molecules that regulate the immune response are showing encourages results and they are rapidly moving into efficacy studies. In this review we present the advances in the use of MAb for the treatment of NHL.